# Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders

> **NCT00992459** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 46 (actual)

## Conditions studied

- Urea Cycle Disorders

## Interventions

- **DRUG:** HPN-100
- **DRUG:** Buphenyl (NaPBA)

## Key facts

- **NCT ID:** NCT00992459
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2024-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00992459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00992459, "Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00992459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*